Insmed, Inc. $INSM Shares Sold by Long Focus Capital Management LLC

Long Focus Capital Management LLC reduced its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 35.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 338,000 shares of the biopharmaceutical company’s stock after selling 182,200 shares during the quarter. Insmed makes up approximately 1.6% of Long Focus Capital Management LLC’s holdings, making the stock its 14th largest holding. Long Focus Capital Management LLC’s holdings in Insmed were worth $48,675,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Kingsview Wealth Management LLC grew its holdings in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the last quarter. Choreo LLC lifted its position in Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 65 shares during the period. Spire Wealth Management lifted its position in Insmed by 11.5% during the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 80 shares during the period. MassMutual Private Wealth & Trust FSB grew its stake in Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 81 shares during the last quarter. Finally, Moody Aldrich Partners LLC grew its stake in Insmed by 2.4% during the 3rd quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after purchasing an additional 132 shares during the last quarter.

Insmed Price Performance

NASDAQ:INSM opened at $144.60 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The company has a 50 day moving average price of $154.57 and a 200-day moving average price of $166.22. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The firm has a market cap of $31.17 billion, a price-to-earnings ratio of -22.56 and a beta of 1.13.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. During the same period last year, the company posted ($1.32) earnings per share. The business’s quarterly revenue was up 152.6% on a year-over-year basis. Equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analysts Forecast Growth

INSM has been the subject of a number of research reports. Wolfe Research set a $167.00 target price on Insmed and gave the stock an “outperform” rating in a report on Thursday, December 18th. Royal Bank Of Canada raised their price target on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Citigroup restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Barclays started coverage on shares of Insmed in a report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price objective on the stock. Finally, Bank of America set a $203.00 target price on shares of Insmed in a report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $205.57.

Insider Activity

In other news, CFO Sara Bonstein sold 748 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $116,942.32. Following the sale, the chief financial officer directly owned 79,758 shares in the company, valued at $12,469,365.72. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Alexander Smith sold 640 shares of Insmed stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total value of $100,012.80. Following the completion of the transaction, the insider owned 56,397 shares of the company’s stock, valued at approximately $8,813,159.19. This represents a 1.12% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 189,651 shares of company stock valued at $31,784,545. Insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.